194 related articles for article (PubMed ID: 29720734)
1. Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.
Halpern AB; Othus M; Huebner EM; Scott BL; Becker PS; Percival MM; Hendrie PC; Gardner KM; Chen TL; Buckley SA; Orlowski KF; Anwar A; Appelbaum FR; Erba HP; Estey EH; Walter RB
Leukemia; 2018 Nov; 32(11):2352-2362. PubMed ID: 29720734
[TBL] [Abstract][Full Text] [Related]
2. Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
Halpern AB; Othus M; Huebner EM; Buckley SA; Pogosova-Agadjanyan EL; Orlowski KF; Scott BL; Becker PS; Hendrie PC; Chen TL; Percival MM; Estey EH; Stirewalt DL; Walter RB
Leukemia; 2017 Dec; 31(12):2560-2567. PubMed ID: 28555084
[TBL] [Abstract][Full Text] [Related]
3. Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.
Halpern AB; Rodríguez-Arbolí E; Othus M; Garcia KA; Percival MM; Cassaday RD; Oehler VG; Becker PS; Appelbaum JS; Abkowitz JL; Orozco JJ; Keel SB; Hendrie PC; Scott BL; Ghiuzeli MC; Estey EH; Walter RB
Blood Adv; 2023 Sep; 7(17):4950-4961. PubMed ID: 37339483
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.
Wang AY; Weiner H; Green M; Chang H; Fulton N; Larson RA; Odenike O; Artz AS; Bishop MR; Godley LA; Thirman MJ; Kosuri S; Churpek JE; Curran E; Pettit K; Stock W; Liu H
J Hematol Oncol; 2018 Jan; 11(1):4. PubMed ID: 29304833
[TBL] [Abstract][Full Text] [Related]
5. Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms.
Godwin CD; Rodríguez-Arbolí E; Othus M; Halpern AB; Appelbaum JS; Percival MM; Hendrie PC; Oehler VG; Keel SB; Abkowitz JL; Cooper JP; Cassaday RD; Estey EH; Walter RB
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740603
[TBL] [Abstract][Full Text] [Related]
6. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.
Visani G; Milligan D; Leoni F; Chang J; Kelsey S; Marcus R; Powles R; Schey S; Covelli A; Isidori A; Litchman M; Piccaluga PP; Mayer H; Malagola M; Pfister C
Leukemia; 2001 May; 15(5):764-71. PubMed ID: 11368437
[TBL] [Abstract][Full Text] [Related]
7. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
Karp JE; Smith BD; Levis MJ; Gore SD; Greer J; Hattenburg C; Briel J; Jones RJ; Wright JJ; Colevas AD
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4467-73. PubMed ID: 17671131
[TBL] [Abstract][Full Text] [Related]
8. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Giebel S; Skotnicki AB; Piatkowska-Jakubas B; Kuliczkowski K; Kiełbiński M; Zawilska K; Kłoczko J; Wrzesień-Kuś A;
Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637
[TBL] [Abstract][Full Text] [Related]
9. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.
Kadia TM; Cortes J; Ravandi F; Jabbour E; Konopleva M; Benton CB; Burger J; Sasaki K; Borthakur G; DiNardo CD; Pemmaraju N; Daver N; Ferrajoli A; Wang X; Patel K; Jorgensen JL; Wang S; O'Brien S; Pierce S; Tuttle C; Estrov Z; Verstovsek S; Garcia-Manero G; Kantarjian H
Lancet Haematol; 2018 Sep; 5(9):e411-e421. PubMed ID: 30115541
[TBL] [Abstract][Full Text] [Related]
10. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
[TBL] [Abstract][Full Text] [Related]
11. Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia.
DeAngelo DJ; Jonas BA; Liesveld JL; Bixby DL; Advani AS; Marlton P; Magnani JL; Thackray HM; Feldman EJ; O'Dwyer ME; Becker PS
Blood; 2022 Feb; 139(8):1135-1146. PubMed ID: 34543383
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
[TBL] [Abstract][Full Text] [Related]
13. Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.
Sternberg DW; Aird W; Neuberg D; Thompson L; MacNeill K; Amrein P; Shulman LN
Cancer; 2000 May; 88(9):2037-41. PubMed ID: 10813714
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.
Koc Y; Oyan B; Kars A; Tekuzman G; Canpinar H; Kansu E
Hematol Oncol; 2004 Jun; 22(2):43-53. PubMed ID: 15386563
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
Wrzesień-Kuś A; Robak T; Wierzbowska A; Lech-Marańda E; Pluta A; Wawrzyniak E; Krawczyńska A; Kuliczkowski K; Mazur G; Kiebiński M; Dmoszyńska A; Wach M; Hellmann A; Baran W; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S;
Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia.
DeAngelo DJ; Brunner AM; Werner L; Avigan D; Fathi AT; Sperling AS; Washington A; Stroopinsky D; Rosenblatt J; McMasters M; Luptakova K; Wadleigh M; Steensma DP; Hobbs GS; Attar EC; Amrein PC; Ebert BL; Stone RM; Ballen KK
Am J Hematol; 2018 Feb; 93(2):254-261. PubMed ID: 29119643
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.
Halpern AB; Othus M; Huebner EM; Scott BL; Hendrie PC; Percival MM; Becker PS; Smith HA; Oehler VG; Orozco JJ; Cassaday RD; Gardner KM; Chen TL; Buckley SA; Orlowski KF; Anwar A; Estey EH; Walter RB
Haematologica; 2019 Apr; 104(4):e143-e146. PubMed ID: 30409798
[No Abstract] [Full Text] [Related]
18. Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Walti CS; Halpern AB; Xie H; Kiem ES; Chung EL; Schonhoff KG; Huebner EM; Delaney C; Liu C; Pergam SA; Cheng GS; Kimball LE; Leisenring WM; Boeckh M; Walter RB; Hill JA
Leukemia; 2023 Feb; 37(2):298-307. PubMed ID: 36509892
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
Wrzesień-Kuś A; Robak T; Lech-Marańda E; Wierzbowska A; Dmoszyńska A; Kowal M; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Maj S; Hellmann A; Skotnicki A; Jedrzejczak W; Kuliczkowski K;
Eur J Haematol; 2003 Sep; 71(3):155-62. PubMed ID: 12930315
[TBL] [Abstract][Full Text] [Related]
20. Acute myelogenous leukaemia in older patients at St Bartholomew's Hospital: outcome with mitoxantrone and cytarabine.
Dalley CD; Lillington DL; Bradburn M; Carter M; Amess JA; Rohatiner AZ; Lister TA
Hematol J; 2002; 3(5):237-43. PubMed ID: 12391541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]